W-L Expects Neurontin Sales To Reach $800 Mil. And Hold Through 2000
Warner-Lambert expects its anti-epileptic product Neurontin (gabapentin) to grow by more than 50% to $800 mil. this year and hold that level through its patent expiration year of 2000, the company said at a May 18 meeting with the New York Society of Securities Analysts.
You may also be interested in...
Second quarter sales of Warner-Lambert's Neurontin (gabapentin) climbed 69% over the year-ago quarter, the company reported.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011